Bioequivalence study of Azithromycin 500 mg tablet
Not Applicable
- Conditions
- In the present study, no diseases will be examined and products will be administered by healthy volunteers..
- Registration Number
- IRCT20210519051345N4
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart and Kidney),
Age (20-60)
Exclusion Criteria
Smoking,
history of cardiovascular, liver and kidney disease,
pregnancy,
alcohol and drug addiction,
history of drug allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma Drug Concentration. Timepoint: 0.5-72 hours in predetermined time intervals after drug administration (0.5, 1, 1.5, 2, 2.5, 3, 3.5,4, 4.5, 5, 5.5, 6, 8, 10, 24, 48, 72 h). Method of measurement: HPLC.
- Secondary Outcome Measures
Name Time Method